Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating)’s share price fell 10% during mid-day trading on Tuesday . The company traded as low as $4.41 and last traded at $4.43. 351,489 shares traded hands during mid-day trading, an increase of 51% from the average session volume of 233,420 shares. The stock had previously closed at $4.92.
Analyst Upgrades and Downgrades
Separately, Maxim Group initiated coverage on shares of Zevra Therapeutics in a research note on Friday, March 17th. They issued a “buy” rating and a $12.00 price target on the stock.
Zevra Therapeutics Price Performance
The company has a market capitalization of $153.01 million, a P/E ratio of -3.69 and a beta of 2.21. The stock’s fifty day moving average is $5.31. The company has a quick ratio of 7.93, a current ratio of 7.93 and a debt-to-equity ratio of 0.15.
Insider Buying and Selling
About Zevra Therapeutics
Zevra Therapeutics, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
- Get a free copy of the StockNews.com research report on Zevra Therapeutics (ZVRA)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.